Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORγt gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis.

Ateke Mousavi Nasl-KhamenehAbbas MirshafieyAbdorreza Naser MoghadasiReza ChahardoliMaryam MahmoudiKarim ParastoueiMir Saeid YekaninejadAli Akbar Saboor-Yaraghi

Published in: Neurological research (2017)

These results indicate that both DHA and ATRA might help control disease progression in IFN-β treated RRMS patients with the strongest effects produced by a combination of the two compounds.

Keyphrases

multiple sclerosis
gene expression
fatty acid
white matter
immune response
disease activity